ANNX
NASDAQ · Biotechnology
Annexon Inc
$5.41
-0.19 (-3.39%)
Open$5.63
Previous Close$5.60
Day High$5.70
Day Low$5.39
52W High$7.18
52W Low$2.03
Volume—
Avg Volume2.58M
Market Cap886.39M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+654.3% upside
Current
$5.41
$5.41
Target
$40.81
$40.81
$23.52
$40.81 avg
$51.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 226.99M | 205.43M | 221.74M |
| Net Income | -28,556,645 | -21,219,491 | -26,718,856 |
| Profit Margin | -12.6% | -10.3% | -12.1% |
| EBITDA | -33,644,452 | -28,464,345 | -32,841,743 |
| Free Cash Flow | -13,512,889 | -15,079,405 | -14,899,369 |
| Rev Growth | +7.5% | +20.0% | +0.3% |
| Debt/Equity | 0.32 | 0.38 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |